Plus Therapeutics Modifies Security Holders’ Rights

The latest announcement is out from Plus Therapeutics ( (PSTV) ).

On March 4, 2025, Plus Therapeutics, Inc. entered into a Securities Purchase Agreement with various purchasers, resulting in a private placement involving shares and warrants of the company’s common stock. On June 17, 2025, the company and the purchasers agreed to a letter agreement to minimize the dilutive impact of the private placement. This included the cancellation of Series A Warrants, amendment of Series B Warrants, waiver of the Registration Rights Agreement, and the return of certain shares and warrants by the purchasers. These actions are aimed at reducing the potential negative impact on the company’s stockholders’ equity and facilitating future capital raising efforts.

The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.

Spark’s Take on PSTV Stock

According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.

Plus Therapeutics faces significant financial challenges, with consistent losses and negative equity being the most impactful factors. The technical analysis indicates weak momentum, and valuation metrics are poor due to non-profitability. While there are some positive developments from clinical trials and financing highlighted in the earnings call, these are overshadowed by ongoing corporate risks, including potential Nasdaq delisting.

To see Spark’s full report on PSTV stock, click here.

More about Plus Therapeutics

Average Trading Volume: 12,949,954

Technical Sentiment Signal: Sell

Current Market Cap: $10.11M

For a thorough assessment of PSTV stock, go to TipRanks’ Stock Analysis page.